Publications
794
Citations
30,165
Est. group size
~2
Recurring co-author estimate
Active years
51
Publishing since 1976
Typically publishes in teams of ~17 · 3% small-team papers (≤3 authors) · across 70 venues
- Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Journal of Clinical Oncology · 2026
- Evolution of <i>AR</i> and Non- <i>AR</i> Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial
Clinical Cancer Research · 2026
- Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.
Journal of Clinical Oncology · 2026
- Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer
European Urology Open Science · 2026
- Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel
Cancer · 2026
- Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.
Journal of Clinical Oncology · 2026
- Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with <i>BRCA</i> mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.
Journal of Clinical Oncology · 2026
- Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer
JCO Precision Oncology · 2026
- Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Clinical Cancer Research · 2026
- Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients
Cell Reports Medicine · 2026
- PD23-15 SAFETY OF RUCAPARIB VS DOCETAXEL OR SECOND-GENERATION ANDROGEN RECEPTOR PATHWAY INHIBITOR THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND A <i>BRCA</i> MUTATION IN TRITON3
The Journal of Urology · 2026
- Impact of prior treatment setting on the efficacy of rucaparib vs physician’s choice in <i>BRCA</i> -mutated castration-resistant prostate cancer (mCRPC) in TRITON3.
Journal of Clinical Oncology · 2026
- Circulating tumor DNA–based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Analysis of Alliance A031201.
Journal of Clinical Oncology · 2026
- Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).
Journal of Clinical Oncology · 2026
- A phase 2 study of androgen deprivation therapy and the androgen receptor ligand–directed degrader (BMS-986365) prior to radical prostatectomy in patients with high-risk localized prostate cancer.
Journal of Clinical Oncology · 2026
- Journal of Clinical Oncology×102
- European Urology×17
- Annals of Oncology×12
- Urologic Oncology Seminars and Original Investigations×9
- Clinical Genitourinary Cancer×8
- Phoebe A. Tsao
Medicine · University of Michigan
- Zachary Reichert
Medicine · University of Michigan
- Joshi J. Alumkal
Medicine · University of Michigan
- Zachery R. Reichert
Medicine · University of Michigan
- Arul M. Chinnaiyan
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile